Wegovy side effects in women: myths, facts and when to seek help

The biggest myth: side effects are random and unpredictable

The misconception that derails more women than any other is that Wegovy side effects are a lottery, that some people sail through and others are floored for months with no pattern and no warning. The clinical trials tell a different story. In STEP 1, the 68-week phase-3 trial of semaglutide 2.4mg published in the New England Journal of Medicine, side effects were overwhelmingly gastrointestinal, most common during dose escalation, and generally mild to moderate in severity. The timing is predictable: nausea, stomach discomfort, softer stools or constipation tend to appear in the first week or two after each dose step, then ease as the body adjusts. That pattern does not mean side effects are trivial, they are real, and for some women they are significant enough to pause or slow titration. But knowing they are tied to dose changes rather than a permanent baseline is genuinely useful. Eating smaller meals, avoiding rich or fatty food, and staying hydrated all help. If nausea is disrupting daily life, the right move is to speak with your prescriber about slowing the escalation schedule, not stopping without advice. You can read a broader breakdown of the full Wegovy side effects profile for context beyond the women-specific picture.

What is actually different for women: hormones, hair and contraception

There are a handful of areas where women's experience of Wegovy diverges from the general picture, and they deserve honest attention. Hair thinning (technically telogen effluvium) is one of the most-searched concerns, and it is real: some women notice increased shedding roughly two to four months into treatment, and our dedicated guide to Wegovy and hair loss in women covers why it happens and what to expect in detail. If you want to understand more about whether Wegovy causes hair loss in women and why it happens, the short answer is that it is generally attributed to the physiological stress of rapid calorie deficit and weight change rather than the medicine acting on hair follicles directly, and it typically reverses once weight stabilises. It is worth flagging to your prescriber nonetheless. On contraception: NHS guidance makes clear that there is currently no evidence semaglutide reduces the effectiveness of oral contraceptives, this is a concern more specifically associated with tirzepatide, not semaglutide. Women planning a pregnancy should know that Wegovy is not recommended during pregnancy, breastfeeding or when trying to conceive; a wash-out period is advised before attempting conception, and your prescriber will discuss contraception as part of any review. HRT users should also raise their current regimen at consultation, as NHS England's guidance on weight-management injections addresses both HRT and contraception considerations for GLP-1 medicines.

When to get medical help, not a drill

Most side effects on Wegovy are uncomfortable rather than dangerous, but a few signals need prompt attention. Severe stomach pain that builds gradually and radiates towards the back, with or without vomiting, can indicate acute pancreatitis, a rare but serious condition. The MHRA Drug Safety Updates flagged this specifically for GLP-1 medicines in January 2026, and the message is straightforward: stop treatment and seek urgent medical help if you develop that kind of pain. Other reasons to contact a doctor or call 111 without delay include signs of a serious allergic reaction (swollen face, throat tightening, difficulty breathing), symptoms of gallstones (upper-right abdominal pain, fever, jaundice), and severe dehydration from prolonged vomiting or diarrhoea, particularly relevant if you have any kidney condition. Low mood or thoughts of self-harm should also prompt contact with your GP or a mental health line. For side effects that are not urgent but feel unfamiliar, you can report them directly to the MHRA via the Yellow Card scheme, patients, not just clinicians, can submit reports, and doing so helps build the safety evidence base for everyone. If you have questions between appointments, our aftercare team is available seven days a week.

How semaglutide's side-effect profile in women compares with what you may have read

Online accounts skew towards extremes (either effortless results or unmanageable nausea) because people with ordinary experiences rarely post. The NHS medicines page for semaglutide lists the common and less-common effects clearly: nausea, vomiting, diarrhoea, constipation, stomach pain, burping, dizziness, fatigue and headache appear in the common category; injection-site reactions and low blood sugar (relevant mainly in people also on certain diabetes medicines) are also documented. Compared with the general semaglutide side-effect profile, women specifically report higher rates of nausea in early weeks (possibly influenced by hormonal fluctuations across the menstrual cycle) though the trial data on this subgroup is still developing. It is also worth knowing that men's experience of Wegovy side effects differs in some respects, so a comparison is available if you have a partner or family member also considering treatment. For most women, the side-effect burden decreases meaningfully after the first month at each dose level. If yours does not, that is a conversation to have with your prescriber, not a reason to push through alone. Our prescribers discuss suitability, side-effect expectations and your personal history as a standard part of every consultation; checking your eligibility is the first step.